ABSTRACT: Our objective was to synthesize an amphiphilic diblock copolymer for micellar delivery of rapamycin. Poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate) (PEG-b-PBC) with different hydrophobic core lengths were synthesized from methoxy poly(ethylene glycol) and 2-methyl-2-benzoxycarbonyl-propylene carbonate through ring-opening polymerization using 1,8-diazabicycloundec-7-ene as a catalyst. The critical micelle concentration of PEG-b-PBC was around 10 −8 M and depends on the hydrophobic core length. Rapamycin was effectively incorporated into micelles and drug loading increased with increasing hydrophobic core length, with maximal drug loading of 10% (w/w, drug/polymer), drug loading efficiency of about 85%, and mean particle size of around 70 nm. The drug release profile was also dependent on the hydrophobic core length and the drug release from PEG 114 -b-PBC 30 micelles was the slowest. We also determined the toxicity of rapamycin micelles on insulinoma (INS-1E) $-cells and human islets. Encapsulation of rapamycin into PEG-b-PBC micelles reduced its toxicity. Biodistribution of rapamycin-loaded PEG-b-PBC micelles was determined after systemic administration into mice. Rapamycin-loaded PEG-b-PBC micelles showed little difference in pharmacokinetics and biodistribution characteristics in mice compared with rapamycin carrying nanosuspension. In conclusion, rapamycin formulated with PEG-b-PBC micelles showed significantly reduced toxicity on INS-1E $-cells and human islets, but had similar biodistribution profiles as those of nanosuspensions.
INTRODUCTION
As an alternative cure for type I diabetes, islet transplantation has made a great progress after the introduction of Edmonton protocol. 1, 2 However, islet allograft recipients show a growing fall in insulin independence, resulting only 10% off insulin at 5 years. 3 This decline may reflect drug toxicity to $-cells. Although rapamycin is being used as an immunosuppressive agent as a part of Edmonton protocol, it is known to be toxic to islet $-cells, reducing cell viability and increasing apoptosis in a dose-and timedependent manner. 4 It also inhibits insulin secretion in vitro 4, 5 and causes insulin resistance in normal rats. 6 Therefore, it is important to reduce the toxicity of rapamycin to human islets as well as its systemic toxicity. Rapamycin (sirolimus) is a lipophilic macrocyclic lactone isolated from the soil bacteria Streptomyces hygroscopicus. 7 Its aqueous solubility is only 2.6 :g/ mL and has no ionizable functional groups in the pH range of 1-10. It can only slightly dissolve in some organic solvents such as N,N-dimethylacetamide, propylene glycol, glycerin, ethanol, polysorbate 80, and polyethylene glycol (PEG) 400. 8, 9 Most of these solubilizing agents are harmful to the liver and kidney and can cause hemolysis and acute hypersensitivity reactions. 10, 11 Therefore, novel approaches are needed to develop clinically acceptable injectable formulations of rapamycin.
Biodegradable polymeric micelles are attractive drug delivery vehicles for hydrophobic drugs, especially because they can solubilize hydrophobic drugs in their core and have the ability to control drug release and delivery. They can effectively deliver the drug to target locations and thus increase the therapeutic effects while reducing side effects. Many amphiphilic diblock copolymers consist of PEG, and biodegradable hydrophobic cores have been reported to be capable of forming micelles such as PEG-b-poly(D, L-lactide) (PEG-b-PDLLA), 12 PEGb-poly(caprolactone), 13 and PEG-b-poly(lactideco-glycolic acid) (PEG-b-PLGA). 14 We recently demonstrated the feasibility of using PEG-b-PDLLA micelles to increase the aqueous solubility of bicalutamide. 15 To further increase drug solubility, we modified the polyester component of PEG-b-polyester copolymer into polyester/polycarbonate copolymer system to synthesize PEG-b-poly(carbonatecolactide) [PEG-b-P(CB-co-LA)], and studied the effect of carbonate content on drug loading. It revealed that adding of the carbonate monomer could increase bicalutamide loading in PEG-b-P(CB-co-LA), which significantly increased the drug loading and decreased drug release rate compared with PEG-b-PLLA. 15, 16 In this study, we synthesized PEGblock-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate) (PEG-b-PBC) diblock copolymer for micellar delivery of rapamycin. PEG-b-PBC with different lengths of hydrophobic core was synthesized and used for preparation of micelles for delivery of rapamycin. The effect of hydrophobic core length on drug loading, particle size, and in vitro drug release was determined. The toxicity of rapamycin-loaded micelles was determined on rat insulinoma (INS-1E) cells and human islets. Finally, the biodistribution profiles of rapamycin PEG-b-PBC micelles were studied in mice and compared with rapamycin nanosuspensions.
MATERIALS AND METHODS

Materials
Rapamycin was purchased from LC Laboratories (Woburn, Massachusetts). 1,8-Diazabicyclo [5.4 .0]-undec-7-ene (DBU), methoxy poly(ethylene glycol) [mPEG, M n = 5000, polydispersity index (PDI) = 1.03], and other reagents were obtained from Sigma-Aldrich (St Louis, Missouri) and used without further purification. 2-Methyl-2-benzyloxycarbonylpropylene carbonate (MBC) was synthesized as described by Danquah et al. 16 
Synthesis of Peg-b-pbc
Poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate) was synthesized as described previously. 17 Briefly, DBU (40 :L) was added to the mixture of given amount of mPEG and MBC dissolved in 10 mL anhydrous CH 2 Cl 2 and reacted under stirring for 3 h. The reaction mixture was then dissolved in CH 2 Cl 2 and precipitated with a large amount of ice-cold diethyl ether and dried under vacuum at room temperature. Using deuterated chloroform (CDCl 3 ) as a solvent, 1 H NMR spectra of PEGb-PBC were recorded on Varian (500 MHz). The chemical shifts were calibrated using tetramethylsilane as an internal reference and given in parts per million.
Gel Permeation Chromatography
The weight-average (M w ) and number-average (M n ) molecular weight and PDI of PEG-b-PBC were determined using a Waters gel permeation chromatography (GPC) system equipped with a differential refractive index detector and a GPC column (AM Gel 103/5, American Polymer Standards Corporation, Mentor, OH). Tetrahydrofuran was used as mobile phase at a flow rate of 1 mL/min. A series of special polystyrene standards (700-40,000 g/mol) were used for calibration.
Differential Scanning Calorimetry
The thermal properties of PEG-b-PBC were determined by differential scanning calorimetry (DSC) (DSC Q2000 module; TA Instrument, New Castle, DE), including glass transition temperature (T g ), melting temperature (T m ), and crystalline temperature (T c ). Samples were placed in aluminum pans under nitrogen heated from 25
• C to 100
• C, then cooled to −70
• C to remove thermal history and heated to 100
• C again at a rate of 5
• C/min.
Critical Micelle Concentration
Using pyrene as a hydrophobic fluorescent probe, the critical micelle concentration (CMC) of PEG-b-PBC was determined with fluorescent spectroscopy. Polymer samples were dispersed in water with concentration ranges from 0.5 to 4.8 × 10 −7 mg/mL and mixed thoroughly with pyrene solution to make pyrene concentration of 6 × 10 −7 M. The fluorescent intensity was recorded with a Molecular Devices SpectraMax M2/M2e spectrofluorometer (Sunnyvale, California) with an E x = 338 nm (I 3 ) and 333 nm (I 1 ), E m = 390 nm. The intensity ratio (I 338 /I 333 ) was plotted against the logarithm of polymer concentration. The CMC value was obtained as the point of intersection of two tangents drawn to the curve at high and low concentrations, respectively.
Preparation of Rapamycin Micelles
Rapamycin-loaded micelles were prepared using the film dispersion method as reported previously. 18, 19 Briefly, 1 mg of rapamycin and 10 mg of PEG 114 -b-PBC 8 , PEG 114 -b-PBC 17 , or PEG 114 -b-PBC 30 were dissolved in 0.4 mL methylene chloride in a glass vial. The mixture was vortexed for 1 min to ensure homogeneity and the solvent was evaporated under N 2 flow to form the film. The glass vials were left in a vacuum oven overnight and 2 mL tridistilled water was added for rehydration of the film. The ensuing formulation was then centrifuged at 13,400 g for 10 min to remove residual free drug. The supernatant was filtered using a 0.22 :m nylon filter.
Morphology and Particle Size
The particle distribution size of PEG-b-PBC micelles with different hydrophobic core length was determined by dynamic light scattering (DLS) (Malvern Nano ZS, Worcestershire, UK). The morphology of PEG-b-PBC micelles was observed using a JEM-100S transmission electron microscope (JEOL USA, Inc., Peabody, MA) using an acceleration voltage of 60 kV. Liquid of micelles was loaded on a copper grid and stained with 1% uranyl acetate. The grid was observed under the electron microscope with magnifications of 75,000×.
Drug Loading and in Vitro Release Profiles
Rapamycin concentration was determined by reversephase high-performance liquid chromatography (RP-HPLC) as previously described with slight modifications, 20 using CLC-ODS-18 column (5 :m, 4.6 × 150 mm; Waters Corporation, Milford, MA) maintained at 25
• C, with an ultraviolet detector at 277 nm. The mixture of 80% methanol and 20% water (v/v) was used as a mobile phase, and delivered at a flow rate of 1.0 mL min −1 . The injection volume was 20 :L and the retention time was about 6.5 min. To determine drug loading, 10 :L of rapamycin-loaded micelle solution was diluted with 80% methanol in water. Drug loading and encapsulation efficiency were then determined using the following equations, respectively. Theoretical loading equals to drug loading when the loading efficiency is 100%. The dialysis technique was employed to study the release of rapamycin from different micelle formulations in phosphate buffered saline (PBS) (pH 7.4) with 0.1% Tween-80. Rapamycin-loaded micelles with a final rapamycin concentration of 0.85 mg/mL were placed into a dialysis tube with a molecular weight cutoff of 8000 Da, and dialyzed against 50 mL PBS (pH 7.4) with 0.1% Tween-80 in a thermo-controlled shaker with a stirring speed of 100 rpm at 37
• C. Samples of 1 mL were withdrawn at specified times and rapamycin concentration was determined by RP-HPLC. The samples taken for measurement were replaced with fresh media and the cumulative amount of drug released into the media at each time point was calculated as the percentage of total drug released to the initial amount of the drug. All experiments were performed in triplicate and the data reported as the mean of three individual experiments.
Toxicity of Rapamycin-loaded Micelles on Rat INS-1E Cells
Insulinoma cells were obtained from Professor Claes B. Wolheim (University Medical Center, Geneva, Switzerland). Cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 media supplemented with 10% fetal bovine serum (FBS), 1% antibioticantimycotic, 1 mM sodium pyruvate, and 0.05 mM 2-mercaptoethanol at 37
• C in humidified environment of 5% CO 2 . Cells were seeded in 96-well plates at a density of 10,000 cells per well 24 h before treatment. Then, cells were treated with drug-loaded micelles, free drug, or equivalent amount of blank micelles for additional 24 h. At the end of treatment, cell culture medium was replaced by 100 :L medium with 0.5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and incubated for 1 h at 37
• C. Then, the medium was carefully removed and 200 :L of DMSO was added into each well to dissolve the formazan crystals. The absorbance was measured in a microplate reader at a wavelength of 560 nm. Cell viability was expressed as the percentage of control group. The Data were reported as the mean of triplicate experiments.
Toxicity on Human Islets
Human islets were received from one of the Islet Cell Resource (ICR) Centers through ICR services for Basic Science Applications, in culture medium at 4
• C. On receiving, the islets were cultured in CMRL-1066 medium containing 10% FBS and 1% penicillin streptomycin at 37
• C in humidified environment of 5% CO 2 . Islets were cultured in 24-well plates at a density of 1000 islets per well. Then, cells were treated with drug-loaded micelles, free drug, or equivalent amount of blank micelles for additional 24 h. The islets without any treatment were used as controls. At the end of treatment, the media was carefully removed from each well using a 1 mL pipette tip. The cells were gently washed once with 400 : warm (37
• C) 1× DPBS (containing Mg 2+ and Ca 2+ ). Four hundred microliters was added per well of 3 :M calcein AM (live dye) or 2.5-5.0 :M propidium iodide (PI, dead dye) diluted in warm (37
• C) 1× DPBS incubated for 30 min at 37
• C. Then, the islets were observed with a fluorescent microscope.
in Vivo Pharmacokinetics and Biodistribution Studies
Animal experiments were performed as per the National Institutes of Health (NIH; http:// grants1.nih.gov/grants/olaw/ references/phspol.htm) and institutional animal care and use guidelines using the approved protocol. Mice (4-6 weeks) were divided into two groups for systemic administration of rapamycin-loaded micelles and rapamycin-loaded nanosuspensions. Rapamycin-loaded nanosuspensions were prepared according to the reported method 21 and the mean particle size of these formulations was around 230 nm. Rapamycin-loaded micelles or rapamycin nanosuspensions were injected into the tail vein of the mice at a single dose of 7.5 mg/kg body weight. At 10, 30 min, 1, 4, 8, and 18 h after injection, 0.5 mL whole blood was collected in heparinized tubes by retro-orbital blood collection. The mice were then sacrificed by cervical dislocation and the hearts, livers, spleens, lungs, kidneys, and Peyer's patches on the wall of intestines were collected and weighed. All the samples were stored at −80
• C before analyzed.
Biosample Preparation
Biosamples were prepared according to the reported method with slight modifications. 22 Whole blood samples (0.5 mL) or tissue samples were transferred to 13 × 100 mm 2 conic tubes and spiked with the internal standard (10 :L of 100 :g/mL of pyrene). Then, 1 mL of acetone was added to the tubes. After vortex mixing for 1 min, 1 mL of zinc sulfate/sodium hydroxide solution (6.25% of zinc sulfate; pH 6.5) was added to the tubes. The tubes were capped, vortex mixed for 1 min, and centrifuged at 2600 × g at 4
• C for 10 min. The supernatants were transferred to clean tubes. 1-Chlorobutane (2 mL) was added to the sample tubes. The tubes were capped, vortex mixed for 1 min, and centrifuged at 2000 × g at 4
• C for 10 min. Afterward, the obtained supernatant was transferred to clean glass tubes and dried under vacuum (Vortex evaporator; Labconco, Kansas City, MO) overnight at room temperature. The dried extracts were reconstituted in 200 :L of mobile phase, analyzed by HPLC as described previously.
Determination of Pharmacokinetic Profiles
The whole blood and different tissue concentrationtime data of rapamycin-loaded micelles and nanosuspensions were analyzed by WinNonlin R pharmacokinetics software (version 5.2, Pharsight Corporation, Mountain View, CA) to calculate the pharmacokinetic parameters. Noncompartmental method was used to estimate the blood and tissue concentrations immediately after intravenous injection (C 0 ), fitted to the whole blood or tissue concentration versus time data. The estimated C 0 was then used with the measured blood or tissue concentrations to calculate the area under the curve (AUC) of blood or tissue concentration versus time. The mean residence time (MRT) was also calculated by noncompartmental pharmacokinetic method. A one-compartmental model was fitted to the whole blood concentration versus time data to calculate the pharmacokinetic parameters of area under the first moment curve, half-life time, clearance, and volume of distribution at steady state.
RESULTS
Synthesis and Characterization of Polymers
1 H NMR spectra of PEG-b-PBC were shown in Figure 1 . The polymerization of PEG-b-PBC was confirmed by the disappearance of peaks at * 4.2 and * 4.6 in the MBC monomer and appearance of a new peak at * 4.3. The following peaks at * 1.2 (CH 3 in BC unit), * 3.6 (CH 2 in PEG), * 4.3(CH 2 in BC main chain), * 5.2 (CH 2 in BC side group), and * 7.3 (phenyl ring) were also observed for the structure confirmation of PEG-b-PBC polymer. Using the peak areas of PEG CH 2 groups at * 3.6 and those of CH 2 in BC main chain at * 4.3, the degree of polymerization and molecular weight of the polymers was calculated and listed in Table 1 . The M n s of PEG-b-PBC polymers with different hydrophobic core lengths determined by 1 H NMR were 7000 g/mol for PEG 114 -b-PBC 8 , 9250 g/mol for PEG 114 -b-PCD 17 , 12,500 g/mol for PEG 114 -b-PBC 30 , respectively. The other characteristics of PEG-b-PBC polymers are summarized in Table 1 . GPC was also used to determine the M w and M n of polymers and their PDI. All of the polymers showed narrow distribution in their molecular weights as revealed by the small value of PDI (1.03-1.15). A combined plot comparing the GPC chromatograms for PEG 114 -b-PBC 8 , PEG 114 -b-PBC 17 , and PEG 114 -b-PBC 30 was shown in Figure 2 . The CMC of PEGb-PBC polymers were determined by fluorescence spectroscopy. PEG 114 -b-PBC 8 , PEG 114 -b-PBC 17 , and PEG 114 -b-PBC 30 had low CMC values of 3.6 × 10 −3 , 7.9 × 10 −4 , and 4.0 × 10 −4 mg/mL, respectively ( Figure 4 and Table 1 ). The CMC of PEG 114 -b-PBC 30 was around 10-folds lower than those of PEG 114 -b-PBC 8 , indicating better stability of micelles prepared from PEG 114 -b-PBC 30 .
The thermal properties of PEG-b-PBC copolymers were determined by DSC. The thermograms of 30 has a T g of −35.7
• C and T c of 6.3
• C, respectively, indicating it is a semicrystalline polymer with both amorphous domain and crystalline domains. 
Preparation and Characterization of Micelles
Poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate) with different hydrophobic core lengths was used to prepare rapamycin-loaded micelles. The amount of rapamycin loading into PEG-b-PBC micelles was determined by HPLC, and the drug loading and encapsulation efficiency were calculated using the equations described in Materials and Methods section and the results were shown in Table 2 . Compared with the low solubility of rapamycin in water (2.6 :g/mL), its solubility was greatly improved by more than 300-folds in PEG 114 -b-PBC 30 micelles (about 850 :g/mL). At theoretical drug loading of 9%, PEG 114 -b-PBC 30 with the longest hydrophobic core length showed the highest drug loading of 8.10% ± 1.46%, which corresponded to drug encapsulation efficiency of 88.35% ± 17.3%. However, PEG 114 -b-PBC 8 with the shortest hydrophobic core had the lowest drug loading of 1.45% ± 0.37% and encapsulation efficiency of 14.75% ± 3.86%. The drug loading density increased with increasing hydrophobic core length.
The mean particle size and size distribution of rapamycin-loaded PEG-b-PBC micelles were determined by DLS. The mean particle sizes, reported as the z-average based on mean intensity, were shown in Table 2 . There was no significant difference in particle size among PEG 114 -b-PBC 8 , PEG 114 -b-PBC 17 , and PEG 114 -b-PBC 30 , the particle size range was from 65 to 75 nm. The morphology and particle size of micelles formed by PEG-b-PBC was determined by TEM ( Figure 5 ), which showed a uniform size distribution with average diameter below 50 nm, which is a little smaller than the z-average diameters obtained by DLS.
The cumulative percentage of rapamycin released from PEG-b-PBC micelles with different hydrophobic core lengths was shown in Figure 6 . Among different PEG-b-PBC micelles, PEG 114 -b-PBC 30 micelles with the longest hydrophobic core length had the slowest drug release. After 48 h, only about 60% of the total drug was released from PEG 114 -b-PBC 30 micelles. However, rapamycin release from PEG 114 -b-PBC 8 and PEG 114 -b-PBC 17 micelles was much faster compared with PEG 114 -b-PBC 30 micelles. About 80% and 50% drug was released from PEG 114 -b-PBC 8 and PEG 114 -b-PBC 17 micelles within 8 h, respectively. Almost all the drug was released within 48 h for both PEG 114 -b-PBC 8 and PEG 114 -b-PBC 17 micelles.
Toxicity of Rapamycin on Rat β-cells and Human Islets
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay was used to determine the effect of polymeric micelles formulation on the toxicity of rapamyicn on INS-1E $-cells. As shown in Figure  7 , free rapamycin reduced INS-1E cell viability in a dose-dependent manner, with half maximal inhibitory concentration of 25 :M. The cell viability was reduced to 13.4% at a rapamycin concentration of 35 :M. In contrast, almost no toxicity was observed in rapamycin formulated in PEG-b-PBC micelles at concentration range from 15 to 50 :M.
Calcein AM/PI staining was used to determine the viability of human islets after treatment with rapamycin. It is based on the ability of calcein AM to be retained within live cells, showing an intense uniform green fluorescence and PI to bind to the nuclei of damaged cells, showing a red color. Thus, more the green fluorescence present, more the live cells present Figure 6 . Effect of hydrophobic core length on rapamycin release from PEG-b-PBC micelles. Release experiments were performed in triplicate in PBS with 0.25% Tween 80 at 37
• C and 100 rpm.
in the islets. As shown in Figure 8 , the fluorescent images of human islets demonstrate increased bright red fluorescence in the islets treated with free rapamycin ( Figure 8b ) compared with untreated control (Figure 8a ). In contrast, less red fluorescence and more green fluorescence was observed in rapamycin-loaded PEG-b-PBC micelles and blank micelles-treated human islets. This result was consistent with the results observed in INS-1E $-cells, indicating that formulation of rapamycin into PEG-b-PBC micelles could reduce the toxicity of rapamycin on $-cells.
Pharmacokinetics and Biodistribution
Following preparation and in vitro characterization of rapamycin-loaded PEG-b-PBC micelles, we determined the pharmacokinetics and biodistribution of this micellar formulation at 10, 30, 60, 240, 480, and 1080 min postinjection into the tail vein of mice. The whole blood concentration-time profiles of rapamycin-loaded PEG 114 -b-PBC 30 micelles and rapamycin nanosuspensions were shown in Figure 9 .
The whole blood concentrations of rapamycin-loaded nanosuspensions decreased first after systemic administration, then increased to C max at 30 min postinjection, and then gradually decreased. The pharmacokinetic parameters were calculated with noncompartment model and listed in Table 3 . No significant difference was observed between rapamycinloaded micelles and nanosuspensions (p > 0.05).
The different tissues (heart, liver, spleen, lung, kidney, and Peyer's patches) concentration-time profiles of rapamycin-loaded PEG 114 -b-PBC 30 micelles and rapamycin nanosuspensions are shown in Figure 10 . There are some minor differences in rapamycin concentration in different organs at some time points between micelles and nanosuspensions; however, there is no significant difference in the overall organ concentration results. The calculated pharmacokinetic parameters are listed in Table 4 . There is no statistical significant difference in MRT and AUC for these two formulations.
DISCUSSION
Polymeric micelles can serve as an attractive alternative for currently used solubilizing agents for dissolving hydrophobic drugs for systemic administration. Stealth properties of hydrophilic component of the micelles could prevent their aggregation and reduced the uptake by the reticuloendothelial system. Hydrophobic drugs are incorporated into the hydrophobic core of polymeric micelles through nonpolar and hydrophobic interaction between drugs and the hydrophobic block of the polymers. The compatibility of drug and hydrophobic block determines the efficiency of drug loading. Therefore, we used PEG-b-PBC to load rapamycin because the presence of aromatic moieties in the hydrophobic block will help to increase the compatibility of polymer and drug with hydrophobic ring structures. 23, 24 In our previous studies, it was found that the solubility of bicalutamide in micelles was significantly increased by adding the polycarbonate moieties into PEG-b-P(CB-co-LA). 16 Similar to our previous study, we also found that the drug loading increased with increasing hydrophobic block length ( Table 2) .
The different hydrophobic interaction between the drug and polymer could also explain the difference in rapamycin release profiles from PEG-b-PBC micelles, wherein the drug release rate decreased with increasing PBC block length. As a consequence, PEG 114 -b-PBC 30 micelles with the longest hydrophobic core length had the slowest rapamycin release. The similar phenomenon was also observed by other researchers. 25, 26 For an example, the long hydrophobic chain length of amphiphilic block copolymers poly(ethyl-2-cyanoacrylate) (PECA) derived from trimethylene carbonate, lactide, and mPEG was reported to slow down the release of 9-nitro-20(S)-camptothecin. 19 The release of drug from polymeric micelles is influenced by several factors including polymer hydrophobic core length and structure, physical state of the core, amount and properties of incorporated drugs, strength of the interaction between drug and hydrophobic core, and location of the drug loading. 27 The drug loaded close to the interface of hydrophobic core and hydrophilic block diffuses faster than drugs loaded deep in the hydrophobic core. As we observed in Figure 5 , PEG 114 -b-PBC 17 and PEG 114 -b-PBC 30 demonstrated a similar release profile at the first 8 h, this is probably due to the fast diffusion of drugs loaded close to the interface. After 8 h, the drug release from PEG 114 -b-PBC 30 was slower than PEG 114 -b-PBC17. Because the diffusion of drugs incorporated deep inside the hydrophobic core is slower from the polymers with longer hydrophobic core than those from polymers with shorter hydrophobic core.
Although rapamycin has been widely used in islet transplantation patients to reduce islet graft rejection, its toxicity on $-cell lines and islets has been reported. 4 In our current study, free rapamycin showed a dose-dependent toxicity on INS-1E $-cell. However, the toxicity of rapamycin was greatly reduced after loading into PEG 114 -b-PBC 30 micelles, which showed significant reduced toxicity on both $-cell lines and human islets (Figures 7 and 8 ). This may be due to the slow release of rapamycin from PEG 114 -b-PBC 30 micelles, which might be helpful to keep rapamycin concentration below toxic level.
Because rapamycin works through the inhibition of T-cell proliferation and maturation, its efficiency will be enhanced by targeted delivery rapamycin into lymphatic system enriched with T cells. Some tissues contain many T cells such as spleen, thymus, and Peyer's patches on the wall of intestines. 28 The walls of lymphatic capillaries consist of a single layer of epithelial cells that enables small particles to be easily taken up by these cells. 29 In recent years, research related to lymphatic targeting has attracted great interest. [30] [31] [32] To enhance immunosuppressive efficiency of tacrolimus and reduce its systemic toxicity, Shin et al. 33 prepared tacrolimus-loaded nanoparticles using PLGA, and PLGA surface-modified with PEG for targeted delivery of tacrolimus into the lymphatic system. It showed that nanoparticles are good candidates for lymphatic delivery of tacrolimus. 33 To determine the biodistribution profiles of PEG-b-PBC micelle-loaded rapamycin, especially the lymphatic targeting efficiencies after intravenous administration, we chose rapamycin nanosuspesions as the control due to the potential lymphatic targeting properties of nanosuspesions. The pharmacokinetic profiles of rapamycin-loaded PEG-b-PBC micelles were similar to those of rapamycin-loaded nanosuspensions, especially the drug accumulation in Peyer's patches (lymph nodes). In contrast, nanosuspensions carrying submicron-sized crystalline drug particles that are stabilized by coatings of surfactant to produce stable pharmaceutical formulations. 34 The drug loaded into nanoparticles may not dissolve readily upon intravenous administration and may be phagocytosed by Kupffer cells and resident macrophages in the liver and spleen. Furthermore, the drug crystals will slowly dissolve and then diffused out of the cells into the extracellular space. These results suggest that these two formulations have similar lymphatic targeting ability. Rapamycin PEG-b-PBC micelles could be used after islet transplantation to suppress the immune rejection with increased therapeutic benefit and reduced toxicity on islet. 33 
